IRIS Accounts Production v24.3.0.553 08989102 Board of Directors 1.5.23 30.4.24 30.4.24 false true false false true false Ordinary A 1.00000 599 2765 4320 6478 4417 4312 696 599 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh089891022023-04-30089891022024-04-30089891022023-05-012024-04-30089891022022-04-30089891022022-05-012023-04-30089891022023-04-3008989102ns15:EnglandWales2023-05-012024-04-3008989102ns14:PoundSterling2023-05-012024-04-3008989102ns10:Director12023-05-012024-04-3008989102ns10:PrivateLimitedCompanyLtd2023-05-012024-04-3008989102ns10:SmallEntities2023-05-012024-04-3008989102ns10:AuditExempt-NoAccountantsReport2023-05-012024-04-3008989102ns10:SmallCompaniesRegimeForDirectorsReport2023-05-012024-04-3008989102ns10:SmallCompaniesRegimeForAccounts2023-05-012024-04-3008989102ns10:FullAccounts2023-05-012024-04-3008989102ns10:OrdinaryShareClass12023-05-012024-04-3008989102ns10:Director2422023-04-3008989102ns10:Director2422022-04-3008989102ns10:Director2422023-05-012024-04-3008989102ns10:Director2422022-05-012023-04-3008989102ns10:Director2422024-04-3008989102ns10:Director2422023-04-3008989102ns5:CurrentFinancialInstruments2024-04-3008989102ns5:CurrentFinancialInstruments2023-04-3008989102ns5:ShareCapital2024-04-3008989102ns5:ShareCapital2023-04-3008989102ns5:RetainedEarningsAccumulatedLosses2024-04-3008989102ns5:RetainedEarningsAccumulatedLosses2023-04-3008989102ns10:RegisteredOffice2023-05-012024-04-3008989102ns5:FurnitureFittings2023-04-3008989102ns5:FurnitureFittings2023-05-012024-04-3008989102ns5:FurnitureFittings2024-04-3008989102ns5:FurnitureFittings2023-04-3008989102ns5:CostValuationns5:ListedExchangeTraded2023-04-3008989102ns5:AdditionsToInvestmentsns5:ListedExchangeTraded2024-04-3008989102ns5:ListedExchangeTradedns5:DisposalsRepaymentsInvestments2024-04-3008989102ns5:RevaluationsIncreaseDecreaseInInvestmentsns5:ListedExchangeTraded2024-04-3008989102ns5:CostValuationns5:ListedExchangeTraded2024-04-3008989102ns5:ListedExchangeTraded2024-04-3008989102ns5:ListedExchangeTraded2023-04-3008989102ns10:OrdinaryShareClass12024-04-3008989102ns10:Director22023-05-012024-04-30089891021ns10:Director12023-04-30089891021ns10:Director12022-04-30089891021ns10:Director12023-05-012024-04-30089891021ns10:Director12022-05-012023-04-30089891021ns10:Director12024-04-30089891021ns10:Director12023-04-30
REGISTERED NUMBER: 08989102 (England and Wales)















Unaudited Financial Statements for the Year Ended 30th April 2024

for

SPS Urology Ltd

SPS Urology Ltd (Registered number: 08989102)






Contents of the Financial Statements
for the Year Ended 30th April 2024




Page

Balance Sheet 1

Notes to the Financial Statements 2


SPS Urology Ltd (Registered number: 08989102)

Balance Sheet
30th April 2024

30.4.24 30.4.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 828 1,325
Investments 5 80,285 75,544
81,113 76,869

CURRENT ASSETS
Cash at bank 14,144 16,240

CREDITORS
Amounts falling due within one year 6 1,293 599
NET CURRENT ASSETS 12,851 15,641
TOTAL ASSETS LESS CURRENT
LIABILITIES

93,964

92,510

PROVISIONS FOR LIABILITIES 157 252
NET ASSETS 93,807 92,258

CAPITAL AND RESERVES
Called up share capital 7 100 100
Retained earnings 93,707 92,158
SHAREHOLDERS' FUNDS 93,807 92,258

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30th April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30th April 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17th January 2025 and were signed on its behalf by:




Dr S I Sriprasad - Director


SPS Urology Ltd (Registered number: 08989102)

Notes to the Financial Statements
for the Year Ended 30th April 2024

1. COMPANY INFORMATION

SPS Urology Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 08989102

Registered office: The Lexicon
Mount Street
Manchester
M2 5NT

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue from the provision of professional services is recognised on delivery of the service.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Tangible Fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment loss.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis:

Fixtures and Fittings - 20% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to the profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


SPS Urology Ltd (Registered number: 08989102)

Notes to the Financial Statements - continued
for the Year Ended 30th April 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and
fittings
£   
COST
At 1st May 2023
and 30th April 2024 2,807
DEPRECIATION
At 1st May 2023 1,482
Charge for year 497
At 30th April 2024 1,979
NET BOOK VALUE
At 30th April 2024 828
At 30th April 2023 1,325

5. FIXED ASSET INVESTMENTS
Listed
investments
£   
COST OR VALUATION
At 1st May 2023 75,544
Additions 3,551
Disposals (1,544 )
Revaluations 2,734
At 30th April 2024 80,285
NET BOOK VALUE
At 30th April 2024 80,285
At 30th April 2023 75,544

SPS Urology Ltd (Registered number: 08989102)

Notes to the Financial Statements - continued
for the Year Ended 30th April 2024

5. FIXED ASSET INVESTMENTS - continued

Cost or valuation at 30th April 2024 is represented by:

Listed
investments
£   
Valuation in 2024 80,285

Market value of listed investments at 30 April 2024 - £80,285 (2023 - £75,543.71). The fixed asset investments represents holdings in listed shares. The listed shares are recognised at market value.

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.24 30.4.23
£    £   
Trade creditors (1 ) 1
Corporation tax payable 598 -
Directors' current accounts 696 598
1,293 599

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.4.24 30.4.23
value: £    £   
100 Ordinary A 1 100 100

8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 30th April 2024 and 30th April 2023:

30.4.24 30.4.23
£    £   
Dr S I Sriprasad and Dr P Aghoram
Balance outstanding at start of year (599 ) (2,765 )
Amounts advanced 4,320 6,478
Amounts repaid (4,417 ) (4,312 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year (696 ) (599 )

The loan is repayable on demand and interest free.

9. CONTROL

The ultimate controlling party is Dr S Sriprasad by virtue of his 70% holding of the voting share capital.